OmniAb Presents New Scientific Data on its OmnidAb™ Platform at the 2023 Antibody Engineering & Therapeutics Conference
2023年12月15日 - 6:30AM
ビジネスワイヤ(英語)
Introduces the functionality and benefits of
the first and only transgenic chicken producing single-domain
antibodies to antibody industry thought leaders and research
scientists from around the world
OmniAb, Inc. (Nasdaq: OABI) announces the presentation of
new scientific data on its OmnidAb™ platform, the industry’s first
and only transgenic chicken host system producing single domain
antibodies (sdAbs), at the 2023 Antibody Engineering &
Therapeutics Conference underway in San Diego and hosted by The
Antibody Society. The Company presented an overview of OmnidAb and
its functionality to industry leaders and prospective customers
today in a presentation by Christine Vuong, Ph.D., Senior
Scientist, titled “Heavy Chain-Only Transgenic Chickens Produce
Human Antibodies with Robust Immune Repertoires and High-Affinity
Binding.”
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20231214937823/en/
(Photo: Business Wire)
“Our recent launch of OmnidAb is the latest example of OmniAb’s
commitment to innovation and the intelligent expansion of our
technology. OmnidAb is the first and only transgenic chicken that
produces single-domain antibodies, which represent an important
class due to their unique physical properties that can be leveraged
for a variety of important applications,” said Matt Foehr, Chief
Executive Officer of OmniAb. “Several current partners are already
leveraging OmnidAb in active programs while many others have
expressed interest in this platform given its versatility in
important applications, including alternate routes of
administration, diagnostic applications and therapeutic approaches
beyond what is typically possible with conventional
antibodies.”
The OmnidAb transgenic chicken novel host system builds upon the
success of the Company’s OmniChicken® legacy by expressing an
optimized single-domain human framework that can generate modular
building blocks well suited to support a variety of therapeutic
modalities. OmnidAb antibodies target distinct epitopes and have
favorable developability profiles with high expression levels in
mammalian cells. Compared with traditional antibodies, sdAbs
produced by OmnidAb chickens have a compact format that opens new
opportunities and broad clinical applications.
“We believe the OmnidAb platform offers significant benefits due
to its built-in use of an optimized human scaffold combined with
efficient in vivo affinity maturation. This minimizes the need for
downstream engineering and provides a functionally diverse immune
repertoire that is unavailable from mammalian systems. There is
growing industry interest in this modality, and we look forward to
working with partners to advance their programs leveraging our new
OmnidAb technology,” added Bill Harriman, Ph.D., Senior Vice
President, Antibody Discovery of OmniAb.
OmniAb is showcasing OmnidAb and its entire technology stack at
the 2023 Antibody Engineering & Therapeutics Conference at
booth #300 at the Marriott Marquis San Diego Marina.
In addition, the Company will be highlighting its OmniDeep™
suite of in silico tools at the Conference in a presentation titled
“Wrangling Diverse OmniAb Antibody Repertoires with OmniDeep” on
Friday, December 15th at 12:05 p.m. Pacific time. OmniDeep
integrates the Company’s Biological Intelligence™ with AI and uses
in silico tools to better mine diverse immune repertoires. Bob
Chen, Senior Director, Discovery Systems, will present a case study
showcasing OmniDeep’s ability to empower large-scale antibody
discovery while selecting high-affinity clones. OmniAb is
leveraging its technology stack to offer partners new discovery
workflows and optimization tools for existing discovery campaigns.
For more information about OmniAb’s proprietary technologies,
please visit www.omniab.com or contact our business development
team at bd@omniab.com.
About OmniAb®
OmniAb’s discovery platform provides pharmaceutical industry
partners access to diverse antibody repertoires and high-throughput
screening technologies to enable discovery of next-generation
therapeutics. At the heart of the OmniAb platform is the Biological
Intelligence™ (BI) of our proprietary transgenic animals, including
OmniRat®, OmniChicken® and OmniMouse® that have been genetically
modified to generate antibodies with human sequences to facilitate
development of human therapeutic candidates. OmniFlic® (transgenic
rat) and OmniClic® (transgenic chicken) address industry needs for
bispecific antibody applications through a common light chain
approach, and OmniTaur™ features unique structural attributes of
cow antibodies for complex targets. OmnidAb™ is an in vivo platform
for single domain antibodies based upon a human VH scaffold that
affinity matures in a chicken host environment to provide a
functionally diverse immune repertoire unavailable from mammalian
systems. We believe the OmniAb animals comprise the most diverse
host systems available in the industry and they are optimally
leveraged through computational antigen design and immunization
methods, paired with high-throughput single B cell phenotypic
screening and mining of next-generation sequencing datasets with
custom algorithms to identify fully human antibodies with superior
performance and developability characteristics. These proprietary
technologies are joined with and leverage OmniDeep™, which is a
suite of in silico tools for therapeutic discovery and optimization
that are woven throughout OmniAb’s various technologies and
capabilities. Additionally, an established core competency focused
on ion channels and transporters further differentiates OmniAb’s
technology and creates opportunities in many emerging target
classes. OmniAb antibodies have been leveraged across modalities,
including bispecific antibodies, antibody-drug conjugates and
others.
The OmniAb suite of technologies span from BI-powered repertoire
generation to cutting-edge antibody discovery and optimization
offering a highly efficient and customizable end-to-end solution
for the growing discovery needs of the global pharmaceutical
industry.
For more information, please visit www.omniab.com.
Forward-Looking Statements
OmniAb cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. Words such as “may,” “will,” “should,”
“expect,” “plan,” “anticipate,” “could,” “intend,” “target,”
“project,” “contemplates,” “believes,” “estimates,” “predicts,”
“potential” or continue” and similar expressions, are intended to
identify forward-looking statements. The forward-looking statements
are based on our current beliefs and expectations and include, but
are not limited to: statements regarding the growth prospects of
our business and the discovery needs of the pharmaceutical
industry; the expected performance of, our technologies and the
opportunities they may create; and the ability to add new partners
and programs. Actual results may differ from those set forth in
this press release due to the risks and uncertainties inherent in
our business, including, without limitation: our future success is
dependent on acceptance of our technology platform and technologies
by new and existing partners, as well as on the eventual
development, approval and commercialization of products developed
by our partners for which we have no control over the development
plan, regulatory strategy or commercialization efforts;
biopharmaceutical development is inherently uncertain; risks
arising from changes in technology; the competitive environment in
the life sciences and biotechnology platform market; our failure to
maintain, protect and defend our intellectual property rights;
difficulties with performance of third parties we will rely on for
our business; regulatory developments in the United States and
foreign countries; unstable market and economic conditions, may
have serious adverse consequences on our business, financial
condition and stock price; and other risks described in our prior
press releases and filings with the SEC, including under the
heading “Risk Factors” in our annual report on Form 10-K and any
subsequent filings with the SEC. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof, and we undertake no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary
statement, which is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231214937823/en/
OmniAb, Inc. Neha Singh, Ph.D. investors@OmniAb.com X (Twitter)
@OmniAbTech (510) 768-7760
OmniAb (NASDAQ:OABI)
過去 株価チャート
から 5 2024 まで 6 2024
OmniAb (NASDAQ:OABI)
過去 株価チャート
から 6 2023 まで 6 2024